BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by Deutsche Bank AG

Deutsche Bank AG boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 12.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 519,217 shares of the biotechnology company's stock after buying an additional 58,687 shares during the quarter. Deutsche Bank AG owned approximately 0.25% of BioCryst Pharmaceuticals worth $3,905,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of BCRX. Vanguard Group Inc. increased its holdings in BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after buying an additional 1,583,826 shares during the period. Eversept Partners LP grew its holdings in BioCryst Pharmaceuticals by 269.9% in the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock worth $14,892,000 after purchasing an additional 1,444,907 shares during the last quarter. Hillsdale Investment Management Inc. grew its holdings in BioCryst Pharmaceuticals by 65,213.3% in the fourth quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company's stock worth $4,077,000 after purchasing an additional 541,270 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in BioCryst Pharmaceuticals in the fourth quarter worth $3,983,000. Finally, Norges Bank purchased a new position in BioCryst Pharmaceuticals in the fourth quarter worth $3,947,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price target on the stock. Barclays lifted their price target on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $13.00 price target (up from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. lifted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Trading Up 3.2%

Shares of NASDAQ:BCRX traded up $0.32 on Thursday, hitting $10.39. 5,656,407 shares of the company were exchanged, compared to its average volume of 3,021,730. BioCryst Pharmaceuticals, Inc. has a 1-year low of $5.92 and a 1-year high of $11.11. The stock's 50 day moving average price is $8.32 and its 200 day moving average price is $8.02. The firm has a market capitalization of $2.17 billion, a P/E ratio of -17.03 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. BioCryst Pharmaceuticals's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.28 EPS. On average, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.